PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

BACKGROUND: Several targeted immunotherapies have recently showed significant advances in treatment of non-small cell lung cancer (NSCLC), including antibodies and inhibitors targeting programmed death-1 (PD-1) and its ligand (PD-L1). METHODS: Tumor tissue samples were prospectively collected from 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yanhui, Liu, Quanxing, Chen, Zhiming, Wang, Yating, Yang, Wanning, Hu, Ying, Han, Wenbo, Zeng, Hui, Ma, Haitao, Dai, Jigang, Zhang, Henghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518807/
https://www.ncbi.nlm.nih.gov/pubmed/31088500
http://dx.doi.org/10.1186/s13046-019-1192-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518807/
https://www.ncbi.nlm.nih.gov/pubmed/31088500
http://dx.doi.org/10.1186/s13046-019-1192-1

Ejemplares similares